

Company showcases | Pitches | Expert insights | Networking



# WELCOME!

*Welcome! We are truly proud to welcome you to the second edition of the Global Forum. This event was created to serve as a melting pot for professionals who have, or would like to, expand into new markets, form global partnerships and attract international capital. The stage content, outlined in this program, aims to help with that, through panels, keynotes and company presentations.*

*We hope you will enjoy these two days.*

**#GlobalForum2025**

---

## MODERATORS



**Cecilia Hallström**

Moderator & Studio  
Manager at BioStock



**Jonas Söderström**

Moderator & CEO  
at BioStock

Ask questions during the event.  
Press here

## ABOUT BIOSTOCK



BioStock is Scandinavia's leading digital news and analytics service, focusing exclusively on the life science sector. Through our editorial coverage, both listed and private companies get the opportunity to keep the market informed and reach out to shareholders, new investors, industry specialists and other stakeholders.

By continuously updating and educating the market about the

life science ecosystem and its key players, BioStock aims to increase understanding and support investors' interest in this dynamic industry and the exciting research taking place in the Nordic region. We do this by providing life science companies at every level an opportunity to reach out to market players via a niche digital media channel with a relevant and engaged target group.

**[www.biostock.se](http://www.biostock.se)**

---

**SUBSCRIBE TO BIOSTOCK'S NEWSLETTERS**

## PROGRAMME | Day 1 | Tuesday | May 20

— Morning session

**09:30 Registration & Coffee**

**10:00 Welcoming notes – BioStock**

**10:05 Keynote: Trump, Tariffs & Rising Uncertainty -  
A Roadmap for Healthcare Companies**

Andreas Dirnagl, Sr Advisor Healthcare, DNB

**10:45 Company presentations**

*Senzime • Zerion Pharma • Elicera Therapeutics • Hamlet Biopharma*

**11:45 Lunch & Networking**

## PROGRAMME | Day 1 | Tuesday | May 20

— Afternoon session

### 12:45 **Market entry:**

#### ***Navigating price pressures and value demonstration***

Karl Arnberg, Global Director of Evidence & Access Policy, Novartis

Philip Siberg, CEO, Senzime

Fredrik Tiberg, CEO, Camurus

Johan Bolander, Senior Pricing & Reimbursement Mgr, Pfizer

Moderator: Nina Rawal, Partner & Co-Head of Ventures, Trill Impact

### 13:30 **Company presentations**

Suturion • Oncopeptides

### 14:00 **Coffee break & Networking**

### 14:30 **Health & Wealth: Live podcast**

Nina Rawal, Partner & Co-Head of Ventures, Trill Impact

### 15:00 **Company presentations**

NextCell Pharma • Annexin Pharmaceuticals • Gasporox

### 15:45 **Coffee break & Networking**

### 16:00 **Company presentations**

Isofol Medical • Xintela

### 16:30 **Sealing the Deal:**

#### ***Lessons from partnering with Big Pharma***

Eva Dahlén, Sr Director Search & Evaluation Diabetes, Novo Nordisk

Jonathan Sjögren, Search & Evaluation Director, AstraZeneca

Lasse Holm Lauridsen, Alliance Management, Genmab

Jesper Lykkesfeldt, Legal Advisor, Business & Corporate Development

Thomas Feldthus, CEO, Saniona

Moderator: Tara Heitner, Co-Chair, Nordic Pharma Licensing Group

### 17:10 **Closing remarks – BioStock**

### 17:30 **Executive Dinner & Networking (Invite only)**

## PROGRAMME | Day 2 | Tuesday | May 21

— Morning session

**08:30 Registration & Coffee**

**09:00 Welcoming notes – BioStock**

**09:05 China:**

### ***An emerging powerhouse of global pharma dealmaking***

Gavin Guo, Vice President of BD, VISEN Pharmaceuticals

Terry Yuan, Senior Vice President, Co-Win Ventures

Jonas Söderström, CEO, BioStock

**09:35 Company presentations**

Lumito • Oxcia • Cinclus Pharma

**10:20 Coffee break & Networking**

**10:50 Health & Wealth: Live podcast**

Claus Johansen, Founder & CEO Global Health Invest

**11:20 Smart money in life science: *Insights from top investors***

Laurenz Govaert, Vice President, EQT Group

Paul Little, Operating Partner, Lundbeckfonden BioCapital

Stephan Christgau, Founding Partner, Eir Ventures

Max Odlander, Partner, HealthCap

Sara Kangaspeska, Investment Director, Innovestor

Moderator: Søren Lemonius, Managing Partner, Sunstone

**12:00 Lunch & Networking**

## **PROGRAMME | Day 2 | Tuesday | May 21**

— Afternoon session

### **13:00 Company presentations**

Simsen Diagnostics • BioInvent International • Xbrane Biopharma

### **13:45 Health & Wealth: Live podcast**

Martin Åmark, CEO Xbrane BioPharma

### **14:15 Coffee break & Networking**

### **14:45 Fireside chat:**

#### ***Global partnering from an IP perspective***

Steve Smith, Managing Partner, Potter Clarkson Group

Søren Bregenholt, CEO Alligator Bioscience

### **15:15 Company presentations**

Alligator BioScience • IRLAB Therapeutics • Abarceo Pharma

### **16:00 A visionary outlook on cancer therapy for 2040**

Mikael Dolsten, former CSO & President Global R&D, Pfizer

Douglas Hanahan, École Polytechnique Fédérale de Lausanne

Moderator: Carl Borrebaeck, Professor, Lund University

### **16:30 Closing remarks – BioStock**

### **16:35 Drinks & Networking**

---

## THIS EVENT WOULD NOT HAVE BEEN POSSIBLE WITHOUT

### PREMIUM EVENT PARTNER



*Your Global CRO Partner in Clinical Research: TFS HealthScience is a global contract research organization that partners with biotechnology and pharmaceutical companies throughout their entire clinical development journey.*

*With industry-leading expertise in key therapeutic areas and demand-driven strategic resourcing, TFS can meet the needs of our partners and sponsors.*

*Our experts are passionate about their disciplines, continually learning, enhancing and dedicating themselves to the success of your trial.*

[www.tfscro.com](http://www.tfscro.com)

## SILVER SPONSORS

---



Potter Clarkson is one of Europe's leading full-service IP law firms. Our sole objective is to help innovators and investors maximise the value of their business or investments by identifying, protecting, exploiting, and enforcing the required IP rights anywhere in the world. With regards to biotechnology and the life sciences, our team is one of Europe's largest.

We are fiercely proud of our reputation as the European IP firm of choice for clients of all sizes, from ambitious start-ups and SMEs through to Big Pharma. Having worked alongside investors in the Nordics, Germany, and the UK for decades we also know to deliver the comprehensive and commercial view of the IP in an investment required to support the best investment decisions.

[www.potterclarkson.com](http://www.potterclarkson.com)



DNB//Back Bay provides healthcare companies with strategic and M&A guidance and execution, licensing and partnering support, a complete range of corporate and investment banking products and services, and full-scale origination and distribution capabilities in global capital markets.

Together, DNB and Back Bay Life Science Advisors hold a unique position bridging the Nordic and US markets, offering support to companies along the full continuum of life science and healthcare.

[www.bbbsa.com/dnb-back-bay-partnership](http://www.bbbsa.com/dnb-back-bay-partnership)



With more than 90 pct. of all US biotech, pharma & life science companies listed on Nasdaq, we know how to match savvy investors with trail-blazing inventors. We are here to support your ideas and the next steps to a public offering that keeps you in control while raising capital to ignite your ambition.

By the way, if you want to keep your ambition closer to home, Nasdaq in the Nordic is the leading hub for listed biotech and health care companies in Europe, with strong support from investors and innovation communities across the region.


How to join the Nasdaq family? Read more here:

[www.nasdaq.com/solutions/listings/markets/nordic/main-market](http://www.nasdaq.com/solutions/listings/markets/nordic/main-market)



*Take the opportunity to ask questions following the company presentations. Simply press the button below.*

Ask questions during the event.  
Press here



---

---

## KEYNOTE

Tuesday, May 20 | 10:05

---

# Trump, Tariffs & Rising Uncertainty

## — A Roadmap for Healthcare Companies

---



**Andreas Dirnagl**  
Sr Advisor Healthcare  
DNB





## COMPANY PRESENTATION

**Date:** Tuesday, May 20  
**Time:** 10:45  
**Presenter:** Philip Siberg, CEO

**CEO** Philip Siberg  
**Chairman** Per Wold-Olsen  
**Industry** Medical Devices

### Focus area

*Senzime is a leading medical technology company at the forefront of a market at an inflection point. The global market transition is driven by new US and EU clinical guidelines and the emergence new technologies.*

*Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurately monitoring neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system secures each patient's precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.*

**Website** [www.senzime.com](http://www.senzime.com)



## COMPANY PRESENTATION

**Date:** Tuesday, May 20  
**Time:** 11:00  
**Presenter:** Ole Wiborg, CEO

**CEO** Ole Wiborg  
**Chairman** Carl-Åke Carlsson  
**Industry** Pharma  
**Focus area** Drug formulation

*ZERION is a pharmaceutical development company focused on improving the bioavailability of oral drug products by increasing their solubility. Improved drug solubility results in significant patient benefits in the form of lower drug doses, fewer side effects and reduction in the number of tablets to be taken. ZERION has multiple research and commercial partnerships with pharma/biotech companies aimed at improving existing marketed medical products as well as completely new drugs applying ZERION's Dispersome® technology. Contrary to current available synthetic chemistry-based solutions, the Dispersome® technology platform is based on using the renewable food protein beta-lactoglobulin (BLG) to enhance drug solubility and bioavailability.*

**Website** [www.zerion.eu](http://www.zerion.eu)




---

## COMPANY PRESENTATION

---

**Date:** Tuesday, May 20

**Time:** 11:15

**Presenter:** Jamal El-Mosleh, CEO

---

**CEO** Jamal El-Mosleh

**Chairman** Agneta Edberg

**Industry** Biotech

**Focus area** Oncology

*Elicera develops next generation armed cancer treatments based on CAR T-cell therapies and oncolytic viruses. The company has two ongoing clinical studies of which one will be reported in mid 2025 (ph I/IIa OV in NET) and one which is ongoing for treatment of B-cell lymphoma (CARMA ph I/IIa - CAR T).*

*Elicera has a runway into second half of 2027, with several important clinical milestones ahead during 2025 and 2026.*

**Website** [www.elicera.com](http://www.elicera.com)



## COMPANY PRESENTATION

**Date:** Tuesday, May 20

**Time:** 11:30

**Presenter:** Catharina Svanborg, Founder & board member

**CEO** Catharina Svanborg

**Chairman** Gabriela Godaly

**Industry** Biotech

**Focus area** Cancer and infections

*Hamlet BioPharma is leveraging highly innovative scientific discoveries and an extensive IP portfolio, to take innovative drugs through mechanistic and preclinical phases, through the development of drug production technology to the clinic. A successfully completed rights issue secured about MSEK 47 in new capital to the company, ensuring continued development of its innovative treatments and rich project portfolio, strengthening our position for discussions with potential commercial partners. Major advances in the clinical program for bladder cancer therapy with Alpha1H show low toxicity and complete or partial response in 82% of the tumors treated. The FDA has granted Alpha1H Fast Track Designation. A recent study within immunotherapy projects shows that treatment effects include severe kidney infections that may cause urosepsis. Importantly, antibiotic resistant bacteria are affected by the treatment, defining this therapy as a possible alternative or complement to antibiotics.*

**Website** [www.hamletbiopharma.com](http://www.hamletbiopharma.com)

---

## PANEL DISCUSSION

Tuesday, May 20 | 12:45 | Moderator: Nina Rawal

---

### Market Entry

— Navigating price pressures and value demonstration

---



**Karl Arnberg**  
Global Director of Evidence &  
Access Policy  
Novartis



**Philip Siberg**  
CEO  
Senzime



**Fredrik Tiberg**  
CEO  
Camurus



**Johan Bolander**  
Pricing & Reimbursement  
Manager  
Pfizer



**Nina Rawal**  
Partner & Co-Head of Ventures  
Trill Impact

---



---

## COMPANY PRESENTATION

---

**Date:** Tuesday, May 20  
**Time:** 13:30  
**Presenter:** Paan Hermansson, CEO

---

**CEO** Paan Hermansson  
**Chairman** Göran Brorsson  
**Industry** Medtech  
**Focus area** Surgery

*Suturion was founded in 2018 by Dr. Gabriel Börner on the idea of developing innovation to enable surgeons to follow the guidelines of the small-bites technique when performing an abdominal wall fascia closure. Recognizing a significant clinical need in this area, we developed SutureTOOL, a groundbreaking medical device designed to help surgeons to perform a standardized, efficient and safe fascia closure.*

*Our vision is to redefine excellence in abdominal wall closure by setting new global standards for safety, efficiency, and cost-effectiveness. Therefore, we strive to develop and commercialize groundbreaking technology to support surgeons, nurses and patients for improved patient outcomes.*

**Website** [www.suturion.com](http://www.suturion.com)



---

## COMPANY PRESENTATION

---

**Date:** Tuesday, May 20  
**Time:** 13:45  
**Presenter:** Sofia Heigis, CEO

---

**CEO** Sofia Heigis  
**Chairman** Per Wold-Olsen  
**Industry** Biotech  
**Focus area** Hematology

*Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients.*

*Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.*

**Website** [www.oncopeptides.com](http://www.oncopeptides.com)

---

## LIVE PODCAST

Tuesday, May 20 | 14:30

---

# HEALTH & WEALTH

a podcast from BioStock about investing in life science

---



**Nina Rawal**  
Partner & Co-Head  
of Ventures  
Trill Impact



**Jonas Söderström**  
Moderator & CEO  
BioStock

[Learn more about our podcast](#)



## COMPANY PRESENTATION

**Date:** Tuesday, May 20  
**Time:** 15:00  
**Presenter:** Mathias Svahn, CEO

**CEO** Mathias Svahn  
**Chairman** Hans-Peter Ekre  
**Industry** Biotech  
**Focus area** Autoimmune diseases

*NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform technology based on allogeneic mesenchymal stromal cells. Using a proprietary selection algorithm, ProTrans delivers optimised cells tailored to specific indications. In type 1 diabetes, a single infusion has been shown to delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being explored in other autoimmune and inflammatory diseases. NextCell's subsidiaries include Cellaviva, Scandinavia's largest private stem cell bank, and QVance, a provider of quality services for advanced therapies.*

**Website** [www.nextcellpharma.com](http://www.nextcellpharma.com)



---

## COMPANY PRESENTATION

---

**Date:** Tuesday, May 20

**Time:** 15:30

**Presenter:** Märta Lewander Xu, PhD

---

**CEO** Märta Lewander Xu

**Chairman** Ulf Sköld

**Industry** Life Science Tools

**Focus area** Pharmaceutical Quality & Inspection Technology

*Gasporox – Advancing Pharmaceutical and Food Quality with Laser-Based Inspection*

*Gasporox is a Swedish technology company specializing in laser-based quality control for pharmaceuticals and food. Our proprietary headspace analysis (HSA) solutions provide non-destructive container closure integrity testing (CCIT) and gas measurement in parenterals, ensuring regulatory compliance and product safety. With a strong global presence, Gasporox continues to expand its portfolio, including inspection for tablets. Our technology helps manufacturers ensure high product quality while optimizing processes and reducing waste.*

**Website** [www.gasporox.se](http://www.gasporox.se)

---



## COMPANY PRESENTATION

**Date:** Tuesday, May 20  
**Time:** 16:00  
**Presenter:** Petter Segelman Lindqvist, CEO

**CEO** Petter Segelman Lindqvist  
**Chairman** Jan-Eric Österlund  
**Industry** Biotech  
**Focus area** Oncology

*Isofol is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of standard treatments for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with a new dosing regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.*

**Website** [isofolmedical.com](https://isofolmedical.com)



---

## COMPANY PRESENTATION

---

**Date:** Tuesday, May 20  
**Time:** 16:15  
**Presenter:** Evy Lundgren-Åkerlund, CEO

---

**CEO** Evy Lundgren-Åkerlund  
**Chairman** Greg Batcheller  
**Industry** Biopharma  
**Focus area** Stem cell therapy, cancer therapy

*Xintela develops and manufactures best-in-class allogeneic stem cell therapies, currently focused on osteoarthritis and wound healing. The human product XSTEM has demonstrated safety and excellent efficacy in an osteoarthritis study, 18 months after treatment. The equine product EQSTEM was recently licensed to EQGen Biomedical Inc. Xintela also offers CDMO advanced therapy product development and manufacturing services.*

*Xintela's subsidiary Targinta, develops targeted first-in-class antibodies and Antibody-Drug Conjugates (ADCs) for the treatment of aggressive and difficult-to-treat tumours including triple-negative breast cancer and glioblastoma. The ADC TARG9 and function blocking antibody TARG10 come with excellent druggable properties and a strong preclinical data package.*

**Website** [xintela.se](https://xintela.se)

## PANEL DISCUSSION

Tuesday, May 20 | 16:30 | Moderator: Tara Heitner

# Sealing The Deal

— Lessons from partnering with Big Pharma



7.

**Jesper Lykkesfeldt**  
Legal Advisor  
LYKKESFELDT



**Lasse Holm Lauridsen**  
Associate Director Alliance Management  
Genmab



**Thomas Feldthus**  
CEO  
Saniona



**Eva Dahlén**  
Sr Director Search & Evaluation Diabetes  
Novo Nordisk



**Tara Heitner**  
Co-Chair  
Nordic Pharma Licensing Group



**Jonathan Sjögren**  
Search & Evaluation Director  
AstraZeneca



**DAY 2**  
**Wednesday**  
**May 21**



---

## PANEL DISCUSSION - HYBRID SESSION

Wednesday, May 21 | 09:05 | Moderator: Jonas Söderström

---

# China: An emerging powerhouse of global pharma dealmaking

---



**Gavin Guo**  
Vice President of  
Business Development  
VISEN Pharmaceuticals



**Terry Yuan**  
Senior Vice President  
Co-Win Ventures



---

## COMPANY PRESENTATION

---

**Date:** Wednesday, May 21  
**Time:** 09:35  
**Presenter:** Sanna Wallenberg, CEO

---

**CEO** Sanna Wallenberg  
**Chairman** Kerstin Jakobsson  
**Industry** MedTech  
**Focus area** Immunohistochemical tissue analysis

*To meet the demand within drug development and precision medicine, Lumito has developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). SCIZYS is a high-sensitivity system that combines labelling and imaging technologies to locate and quantify biomarkers in tissue samples. Lumito's business model provides flexible solutions for a range of applications. Supported by a strong patent portfolio and academic research from Lund University, Lumito aims to advance digital pathology and quantitative tissue analysis through strategic partnerships with CROs and pharmaceutical companies, and collaboration with researchers within academia.*

**Website** [lumito.se](https://lumito.se)



## COMPANY PRESENTATION

**Date:** Wednesday, May 21  
**Time:** 09:50  
**Presenter:** Ulrika Warpman Berglund, CEO

**CEO** Ulrika Warpman Berglund  
**Chairman** Eva Sjökvist Saers  
**Industry** Biotech  
**Focus area** Oncology and inflammation diseases

*Oxcia AB is focusing on two key components for life- DNA and Oxygen- in its unique O2-DDR technology platform. It has potential to cure diseases and extend lives through careful management of oxidative stress, oxidative DNA damage and response in unhealthy cells.*

*The two most advanced projects emanating from the platform are OXC-101 for blood cancer (in clinical Phase 1 /2 trial) and OXC-201 for pulmonary fibrosis (preclinical stage). The portfolio also includes exploratory projects, e.g. in psoriasis.*

*Supporting the projects groundbreaking potentials, Oxcia obtained an EIC transition grant (2.5M Euro) for OXC-201 and FDA recently approved ODD status for OXC-101 in AML.*

**Website** [oxcia.com](https://oxcia.com)




---

## COMPANY PRESENTATION

---

**Date:** Wednesday, May 21

**Time:** 10:05

**Presenter:** Christer Ahlberg, CEO

---

**CEO** Christer Ahlberg

**Chairman** Lennart Hansson

**Industry** Biotech

**Focus area** Gastric acid-related diseases

*Cinclus Pharma is developing linaprazan glurate, the next generation of PCAB that effectively meets the medical needs of the patients who suffer from severe forms of erosive gastroesophageal reflux diseases, eGERD. The potential market for linaprazan glurate among these patients is estimated at 19 million people globally, of which 10 million in Europe and the US. Patient recruitment for the Phase III study is expected to start in the third quarter of 2025 and topline results from the study are expected to be obtained in 2026.*

**Website** [cincluspharma.com](https://cincluspharma.com)

---

---

## LIVE PODCAST

Wednesday, May 21 | 10:50

---

# HEALTH & WEALTH

a podcast from BioStock about investing in life science

---



**Claus Henrik Johansen**  
Founder & CEO  
Global Health Invest



**Jonas Söderström**  
Moderator & CEO  
BioStock

[Learn more about our podcast](#)

## PANEL DISCUSSION

Wednesday, May 21 | 11:20 | Moderator: Søren Lemonius

# Smart Money in Life Science

— Insights from Top Investors



**Paul Little**  
Operating Partner  
Lundbeckfonden BioCapital



Eir Ventures

**Stephan Christgau**  
Founding Partner  
Eir Ventures



**Max Odlander**  
Partner  
HealthCap



**Sara Kangapeska**  
Investment Director  
Innovestor



**Søren Lemonius**  
General Partner  
SunStone Life Science Ventures



EQT  
Life Sciences

**Laurenz Govaert**  
Vice President  
EQT Life Sciences




---

## COMPANY PRESENTATION

---

**Date:** Wednesday, May 21

**Time:** 13:00

**Presenter:** Pontus Rehn, CEO

---

**CEO** Pontus Rehn

**Chairman** Anders Waas

**Industry** Biotech / Diagnostics

**Focus area** Solid tumour cancers

*SimSen Diagnostics is a biotech company that is specialized in ultrasensitive analysis of nucleic acids. SimSen® Personal, the flagship solution, is based on an ultrasensitive sequencing technology capable of detecting minimal residual disease, cancer recurrences, and cancer treatment efficacy, earlier than with any standard-of-care methods. Founded in 2020, SimSen Diagnostics has experienced steady growth, gaining increased recognition from the pharmaceutical industry, CRO's, researchers and clinics alike. Based in Gothenburg, Sweden, the company is at the forefront of providing innovative services in cancer management and monitoring. Personalized assays. Personalized services.*

**Website** [simsendiagnostics.com](https://simsendiagnostics.com)

---



---

## COMPANY PRESENTATION

---

**Date:** Wednesday, May 21  
**Time:** 13:15  
**Presenter:** Björn Frenhéus, CSO

---

**CEO** Martin Welschhof  
**Chairman** Leon Kreumer  
**Industry** Biotech  
**Focus area** Immunotherapy

*BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with five drug candidates in Phase 1/2 clinical trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T<sup>TM</sup> technology platform identifies targets and antibodies that bind to them. It generates promising new immuno-modulatory candidates, fuels the Company's clinical development pipeline, and provides licensing and partnering opportunities.*

*The Company ([www.bioinvent.com](http://www.bioinvent.com)) generates revenues from research collaborations, license agreements with top-tier pharmaceutical companies, and antibody production for third parties in its fully integrated manufacturing unit.*

**Website** [www.bioinvent.com](http://www.bioinvent.com)

---



---

## COMPANY PRESENTATION

---

**Date:** Wednesday, May 21

**Time:** 13:30

**Presenter:** Martin Åmark, CEO

---

**CEO** Martin Åmark

**Chairman** Anders Tullgren

**Industry** Biotech

**Focus area** Biosimilars

**Website** [www.xbrane.com](http://www.xbrane.com)

---

## LIVE PODCAST

Wednesday, May 21 | 13:45

---

# HEALTH & WEALTH

a podcast from BioStock about investing in life science

---



**Martin Åmark**

CEO

Xbrane Biopharma



**Jonas Söderström**

Moderator & CEO

BioStock

[Learn more about our podcast](#)

---

## FIRESIDE CHAT

Wednesday, May 21 | 14:45

---



**Steve Smith**  
Managing Partner  
Potter Clarkson



**Søren Bregenholt**  
CEO  
Alligator BioScience





## COMPANY PRESENTATION

**Date:** Wednesday, May 21  
**Time:** 15:15  
**Presenter:** Søren Bregenholt, CEO

**CEO** Søren Bregenholt  
**Chairman** Anders Ekblom  
**Industry** Biotech  
**Focus area** Immuno-oncology

*Alligator Bioscience is a clinical-stage biotech company advancing breakthrough immuno-oncology therapies. Our lead candidate, mitazalimab, is a Phase 3-ready CD40 agonist for metastatic pancreatic cancer. With encouraging survival data, a confirmed regulatory path, and a favorable safety profile, mitazalimab shows strong potential as a transformative treatment in this high-need indication. Backed by solid clinical momentum, we are actively exploring strategic partnerships to accelerate development and create long-term value for patients and shareholders.*

**Website** [alligatorbioscience.se](https://alligatorbioscience.se)



---

## COMPANY PRESENTATION

---

**Date:** Wednesday, May 21  
**Time:** 15:30  
**Presenter:** Kristina Torfgård, CEO

---

**CEO** Kristina Torfgård  
**Chairman** Carola Lemne  
**Industry** Biopharma  
**Focus area** Neuroscience - Parkinson's diseases

*IRLAB has a world-leading portfolio in Parkinson's disease, with five drug candidates that address disabling complications throughout the course of the disease. All are first-in-class candidates developed with our unique AI-based research platform, Integrative Screening Process (ISP), and have the potential to revolutionize the treatment of Parkinson's disease.*

*With three projects in the clinical phase, two of which are in late-stage development, we are well on our way to our goal of contributing to a higher quality of life for everyone living with Parkinson's and other neurodegenerative diseases.*

**Website** [www.irlab.se](http://www.irlab.se)



---

## COMPANY PRESENTATION

---

**Date:** Wednesday, May 21

**Time:** 15:45

**Presenter:** Adam Bruce, CEO

---

**CEO** Adam Bruce

**Chairman** Adam Bruce

**Industry** Life Science

**Focus area** Mitochondrial Dysfunction

*Abarceo adress mitochondrial dysfuntion. Focus is on restoring function of the beta cell eg insulin production in diabetic patients and achieve a disease modifying treatment for patients.*

*The validity of the target is confimed through two industrial collaborations already in the pre-clinical phase.*

*The company has recruited key competences to management and board. Investors are early stage VC, family office and angel investors.*

*Currently Abarceo is raising a bridge round of approximately 20MSEK*

**Website** [www.abarceo.com](http://www.abarceo.com)

---

## PANEL DISCUSSION

Wednesday, May 21 | 16:00 | Moderator: Carl Borrebaeck

---

# A visionary outlook on cancer therapy for 2040

---



**Dr Mikael Dolsten**  
Former CSO &  
President Global R&D  
Pfizer



**Prof. Douglas Hanahan**  
Director Emeritus  
École polytechnique  
Fédérale de Lausanne



LUND UNIVERSITY

**Prof. Carl Borrebaeck**  
Professor & Entrepreneur  
Lund University

---

## CONTACT US

Would you like to be invited as a guest, present at, or perhaps become a sponsor to one of our upcoming events? Don't hesitate to reach out to our BD representatives below!

### LUND



**Jonas Söderström**

CEO

+46 (0)70 652 42 72

[jonas.soderstrom@biostock.se](mailto:jonas.soderstrom@biostock.se)



**Felix Borrebaeck**

Business Developer

+46 (0)73 031 50 67

[felix.borrebaeck@biostock.se](mailto:felix.borrebaeck@biostock.se)

### STOCKHOLM



**Linus Flink Elmfors**

CBO & Office Manager

+46 (0)73 032 12 18

[linus.flink@biostock.se](mailto:linus.flink@biostock.se)

---



## Connecting Innovation & Capital

PREMIUM EVENT PARTNER

**TFS HEALTHSCIENCE**

SILVER SPONSORS

**POTTER CLARKSON | NASDAQ |**  
**| DNB // BACK BAY |**

SUBSCRIBE TO THE BIOSTOCK NEWSLETTERS



[www.biostock.se](http://www.biostock.se)